4-(4-Aminophenoxy)-N-methyl-2-pyridinecarboxamideCAS# 284462-37-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 284462-37-9 | SDF | Download SDF |
| PubChem ID | 16655129 | Appearance | Powder |
| Formula | C13H13N3O2 | M.Wt | 243.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide | ||
| SMILES | CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)N | ||
| Standard InChIKey | RXZZBPYPZLAEFC-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C13H13N3O2/c1-15-13(17)12-8-11(6-7-16-12)18-10-4-2-9(14)3-5-10/h2-8H,14H2,1H3,(H,15,17) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
4-(4-Aminophenoxy)-N-methyl-2-pyridinecarboxamide Dilution Calculator
4-(4-Aminophenoxy)-N-methyl-2-pyridinecarboxamide Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.1102 mL | 20.5508 mL | 41.1015 mL | 82.203 mL | 102.7538 mL |
| 5 mM | 0.822 mL | 4.1102 mL | 8.2203 mL | 16.4406 mL | 20.5508 mL |
| 10 mM | 0.411 mL | 2.0551 mL | 4.1102 mL | 8.2203 mL | 10.2754 mL |
| 50 mM | 0.0822 mL | 0.411 mL | 0.822 mL | 1.6441 mL | 2.0551 mL |
| 100 mM | 0.0411 mL | 0.2055 mL | 0.411 mL | 0.822 mL | 1.0275 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Sorafenib
Catalog No.:BCN2174
CAS No.:284461-73-0
- 6-Hydroxy-2,6-dimethyl-2,7-octadienoic acid
Catalog No.:BCN1463
CAS No.:28420-25-9
- Ac9-25
Catalog No.:BCC5997
CAS No.:284040-76-2
- NPS-2143
Catalog No.:BCC4409
CAS No.:284035-33-2
- DR 2313
Catalog No.:BCC2451
CAS No.:284028-90-6
- XAV-939
Catalog No.:BCC1120
CAS No.:284028-89-3
- FR 236924
Catalog No.:BCC7564
CAS No.:28399-31-7
- 1(10)-Aristolen-2-one
Catalog No.:BCN7634
CAS No.:28398-06-3
- Bumetanide
Catalog No.:BCC1119
CAS No.:28395-03-1
- 7-Neohesperidosides
Catalog No.:BCN8200
CAS No.:28383-41-7
- Aloin B
Catalog No.:BCN2576
CAS No.:28371-16-6
- Chrysin 6-C-glucoside
Catalog No.:BCN3324
CAS No.:28368-57-2
- Bavachalcone
Catalog No.:BCN3193
CAS No.:28448-85-3
- Tomentin
Catalog No.:BCN5180
CAS No.:28449-62-9
- 20-Deacetyltaxuspine X
Catalog No.:BCN7374
CAS No.:284672-76-0
- 9-Deacetyltaxinine E
Catalog No.:BCN7227
CAS No.:284672-78-2
- Delphinidin-3-O-galactoside chloride
Catalog No.:BCN3019
CAS No.:28500-00-7
- Petunidin-3-O-galactoside chloride
Catalog No.:BCN3024
CAS No.:28500-02-9
- Petunidin-3-O-arabinoside chloride
Catalog No.:BCN3026
CAS No.:28500-03-0
- Malvidin-3-O-arabinoside chloride
Catalog No.:BCN3032
CAS No.:28500-04-1
- Anadoline N-oxide
Catalog No.:BCN2029
CAS No.:28513-29-3
- 1-Amino-2-methylpropan-2-ol
Catalog No.:BCN1773
CAS No.:2854-16-2
- BML-190
Catalog No.:BCC4410
CAS No.:2854-32-2
- Theaflavin-3'-gallate
Catalog No.:BCN5421
CAS No.:28543-07-9
Quantification of Sorafenib in Human Serum by Competitive Enzyme-Linked Immunosorbent Assay.[Pubmed:26521829]
Biol Pharm Bull. 2015;38(11):1788-93.
The multikinase inhibitor sorafenib has been used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma. Here we have demonstrated the production of the first specific antibody against sorafenib. Anti-sorafenib serum was obtained by immunizing mice with an antigen conjugated with bovine serum albumin and carboxylic modified 4-(4-Aminophenoxy)-N-methyl-2-pyridinecarboxamide (AMPC) using the N-succinimidyl ester method. Enzyme labeling of sorafenib with horseradish peroxidase was similarly performed using carboxylic modified AMPC. A simple competitive enzyme-linked immunosorbent assay (ELISA) for sorafenib was developed using the principle of direct competition between sorafenib and the enzyme marker for anti-sorafenib antibody, which had been adsorbed by the plastic surface of a microtiter plate. Serum sorafenib concentrations lower than 0.04 microg/mL were reproducibly measurable using the ELISA. This ELISA was specific to sorafenib and showed very slight cross-reactivity (2.5%) with a major metabolite, sorafenib N-oxide. The values of serum sorafenib levels from 32 patients measured by this ELISA were comparable with those measured by HPLC, and there was a strong correlation between the values determined by the two methods (Y=1.016X-0.137, r=0.979). The specificity and sensitivity of the ELISA for sorafenib should provide a valuable new tool for use in therapeutic drug monitoring and pharmacokinetic studies of sorafenib.
